欧林生物核心产品陷合同诉讼，涉诉金额超半年净利润

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. (Olin Bio, 688319.SH) is facing a lawsuit regarding two core vaccine products, leading to the freezing of some bank accounts by the court [1][2]. Group 1: Lawsuit Details - The plaintiff, Wang Jianhua, is requesting Olin Bio to pay a total of 16 million yuan for commissions related to two vaccine products and an additional 3.2 million yuan in penalties [1]. - Olin Bio has stated that it believes the lawsuit lacks sufficient factual and legal basis and will actively defend itself [2]. - The lawsuit traces back to a technical cooperation agreement signed in 2011, but Olin Bio's IPO prospectus did not mention Wang Jianhua's involvement or the claim for commissions [2][3]. Group 2: Financial Impact - Olin Bio's bank accounts have been partially frozen, with one account holding 19.2 million yuan, which represents 2.06% of the company's latest audited net assets and 8.57% of its cash balance [2]. - The lawsuit's claimed amount exceeds Olin Bio's net profit for the first half of 2025 [5]. - In 2024, Olin Bio reported revenues of 58.89 million yuan, a year-on-year increase of 18.69%, and a net profit of 2.08 million yuan, also up by 18.24% [4].